Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.
2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
3.

Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.

Fleischhacker WW, Siu CO, Bodén R, Pappadopulos E, Karayal ON, Kahn RS; EUFEST study group.

Int J Neuropsychopharmacol. 2013 Jun;16(5):987-95. doi: 10.1017/S1461145712001241. Epub 2012 Dec 20.

PMID:
23253821
4.

Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM.

JAMA Psychiatry. 2014 Dec 1;71(12):1350-63. doi: 10.1001/jamapsychiatry.2014.1314.

PMID:
25321337
5.

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.

Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA.

Schizophr Res. 2008 Apr;101(1-3):273-86. doi: 10.1016/j.schres.2007.12.487. Epub 2008 Feb 6.

6.

Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.

Moeller KE, Rigler SK, Mayorga A, Nazir N, Shireman TI.

Schizophr Res. 2011 Mar;126(1-3):117-23. doi: 10.1016/j.schres.2010.11.015. Epub 2010 Dec 18.

PMID:
21168994
7.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
8.

The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.

Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M.

Int Clin Psychopharmacol. 2011 Nov;26(6):291-302. doi: 10.1097/YIC.0b013e32834a5bf6.

PMID:
21876442
9.

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M.

Psychol Med. 2012 Jan;42(1):125-47. doi: 10.1017/S003329171100105X. Epub 2011 Aug 10. Review.

PMID:
21846426
10.

Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.

Masand PS, Culpepper L, Henderson D, Lee S, Littrell K, Newcomer JW, Rasgon N.

CNS Spectr. 2005 Oct;10(10):suppl14 1-15.

PMID:
16404802
11.

Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.

Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino RB Sr, O'Donnell CJ.

Circulation. 2007 Jul 3;116(1):39-48. Epub 2007 Jun 18.

12.

Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study.

Deuschle M, Paul F, Brosz M, Bergemann N, Franz M, Kammerer-Ciernioch J, Lautenschlager M, Lederbogen F, Roesch-Ely D, Weisbrod M, Kahl KG, Reichmann J, Gross J, Umbreit J.

Soc Psychiatry Psychiatr Epidemiol. 2013 Aug;48(8):1283-8. doi: 10.1007/s00127-013-0676-0. Epub 2013 Mar 21.

PMID:
23515714
13.

Physical health of patients with severe mental illness: an intervention on medium secure forensic unit.

Vasudev K, Thakkar PB, Mitcheson N.

Int J Health Care Qual Assur. 2012;25(4):363-70.

PMID:
22755485
14.

Dysmetabolic features of the overweight patients receiving antipsychotic drugs: a comparison with normal weight and obese subjects.

Manu P, Correll CU, Wampers M, van Winkel R, Yu W, Shiffeldrim D, De Hert M.

Eur Psychiatry. 2014 Mar;29(3):179-82. doi: 10.1016/j.eurpsy.2012.12.001. Epub 2013 Feb 12.

PMID:
23415509
16.

[Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].

Verdoux H, Gaudron Y, Auleley GR, Deligne J, Blum-Boisgard C, Thiébaut A, Tournier M.

Encephale. 2013 May;39 Suppl 1:S22-8. doi: 10.1016/j.encep.2012.10.009. Epub 2012 Dec 13. French.

PMID:
23246328
17.

Non-obese (body mass index < 25 kg/m2) Asian Indians with normal waist circumference have high cardiovascular risk.

Vikram NK, Pandey RM, Misra A, Sharma R, Devi JR, Khanna N.

Nutrition. 2003 Jun;19(6):503-9.

PMID:
12781849
19.

Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.

McIntyre RS, Jerrell JM.

Arch Pediatr Adolesc Med. 2008 Oct;162(10):929-35. doi: 10.1001/archpedi.162.10.929.

PMID:
18838645
20.

Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.

Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A.

Aust N Z J Psychiatry. 2007 Dec;41(12):980-9.

PMID:
17999270

Supplemental Content

Support Center